5:10 PM
 | 
Feb 28, 2014
 |  BC Extra  |  Financial News

Medivation falls on U.S. Xtandi outlook

Medivation Inc. (NASDAQ:MDVN) fell $12.61 (15%) to $71.91 on Friday after introducing 2014 U.S. sales guidance for prostate cancer drug Xtandi enzalutamide that fell short of the Street's expectations. For 2014, Medivation expects U.S. Xtandi net sales of $500-$535 million. According to...

Read the full 198 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >